+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Ibrance 2019 U.S. Promotional Audit Report

  • ID: 5121337
  • Report
  • July 2020
  • Region: United States
  • 21 pages
  • MD Details
1 of 1
The 5 Key Questions Addressed by this Report:
  • How many physicians were reached by Ibrance through reportable promotional activity in 2019 and how does this compare to its peer set in the Breast Cancer market?
  • What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend for each type of activity?
  • How does Pfizer's depth of coverage vary within key specialties (e.g., Hematology/Oncology, Medical Oncology, and Internal Medicine) and how does this compare to its peers and the overall set of rep-accessible physicians?
  • How often are physicians receiving paid meals for Ibrance throughout the year (e.g., monthly, quarterly, annually)?
  • Who were the most frequent meal recipients and top paid speakers for Ibrance in 2019?
Data Sources and Methodology:
  • Author leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. More than five years of longitudinal data is available - covering payments to more than 1,000,000 U.S. healthcare professionals.
  • Over 10,900 paid interactions across 3,100 physicians made on behalf of Ibrance were carefully examined to support our analysis. In addition, interaction data from 16 peer products (i.e. Abraxane, Afinitor, Avastin, Halaven, Herceptin, Kadcyla, Kanjinti, Kisqali, Lynparza, Nerlynx, Ogivri, Perjeta, Piqray, Talzenna, Tecentriq, and Verzenio) was leveraged to provide benchmarking and market insights.
Note: Product cover images may vary from those shown